Hims & Hers Health (HIMS) is turning a Trump administration policy shift into a new line of business. The telehealth company launched Peptides+ on Nov. 18, weeks after federal health officials moved to ease enforcement on the compounding of certain peptides.
At the time of writing, HIMS stock is trading at less than half its price in early July.
Qualifying compounders have room under the Trump administration's interim policy to make some peptides under specified conditions while the FDA considers whether to formally add them to its compounding list.
On Wednesday, HIMS launched Peptides+ with five treatments and said it will soon add BPC-157 and TB-500 as well, in line with regulatory standards.
For investors, the opportunity goes beyond prescriptions. Hims & Hers Health pairs Peptides+ with lab testing and follow-up care, giving customers more reasons to return to its platform.
Management expects peptide revenue to be immaterial in 2026, so the financial benefit primarily hinges on how many customers sign up and stay.
Hims & Hers already has a sizable audience for new services, growing subscribers by 13% in its latest reported quarter to 2.8 million. Monthly revenue per average subscriber also surpassed $100, driven mostly by offerings such as menopause care and testosterone testing.
Plus, a recent deal with Eli Lilly (LLY) also gives eligible patients access to Zepbound and Foundayo through the HIMS platform.
On the flip side, however, gross margin contracted sharply to 57%, raising questions about the firm’s ability to translate growth into profit.
Note that Barchart also currently has a “72% SELL” average opinion on Hims & Hers, signaling technical momentum is not in its favor heading into 2027.
Crucially, Wall Street analysts believe Hims & Hers Health is undervalued at the current price and poised for meaningful recovery next year.
While the consensus rating on HIMS shares sits at Hold, the mean price target of nearly $29 signals potential upside of more than 50% from here.